Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B

Moderna, Inc.

2024-Q2 EPS reported -$6.41 revenue$408,000,000

Revenue $241M vs $344M YoY; net product sales $184M (-37%).
Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.
RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.
Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.
David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.